Clinical Trial Update: Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing eribulin plus cisplatin versus gemcitabine plus cisplatin in triple-negative breast cancer is reported as ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Eribulin (eribulin mesilate)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN